Drugs / HLX12
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03863587 | Jun → Sep 2019 | — | Shanghai Henlius Biotech | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-10-26 | Shanghai Henlius Biotech | Regulatory New Progress! Henlius Received Clinical Approval for Its Anti-VEGFR2 Monoclonal Antibody, HLX12 henlius.com ↗
received the approval to conduct clinical trial for its recombinant fully human monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (HLX12; hereinafter referred to as the New Drug) from the National Medical Products Administration (NMPA) |
| 2018-08-09 | Shanghai Henlius Biotech | Regulatory Henlius Submitted Investigational New Drug Application for Its HLX12 henlius.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-10-26 | Shanghai Henlius Biotech | New Progress! Henlius Received Clinical Approval for Its Anti-VEGFR2 Monoclonal Antibody, HLX12 henlius.com ↗ |
| 2018-08-09 | Shanghai Henlius Biotech | Henlius Submitted Investigational New Drug Application for Its HLX12 henlius.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03863587 ↗ |
| Route | Intravenous | “HLX12 are given intravenous infusion 8 mg/kg” NCT03863587 ↗ |